Alumis (ALMS) Revenue (2025)

Alumis' (ALMS) quarterly Revenue came in at $1.9 million in Q4 2025, down 6.63% on a QoQ basis from $2.1 million in Q3 2025.

Alumis (ALMS) Revenue (2025) Analysis & Trends

Alumis (ALMS) has 1 years of Revenue data on file, last reported at $1.9 million in Q4 2025.

On a quarterly basis, Revenue changed N/A year-over-year to $1.9 million in Q4 2025; TTM through Dec 2025 was $24.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $24.0 million, changed N/A from the prior year.
Revenue for Q4 2025 stood at $1.9 million, down from $2.1 million in the prior quarter.
Over the last five years, Revenue for ALMS reached as high as $17.4 million in Q1 2025 and fell as low as $1.9 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	1.51 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	2.99 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	3.61 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	1.30 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Alumis	2.37 Bn	2.06 Bn	-	1.93 Mn

Download Data